WO2001053457A3 - Vaccines against neurodegenerative disorders - Google Patents

Vaccines against neurodegenerative disorders Download PDF

Info

Publication number
WO2001053457A3
WO2001053457A3 PCT/US2001/001665 US0101665W WO0153457A3 WO 2001053457 A3 WO2001053457 A3 WO 2001053457A3 US 0101665 W US0101665 W US 0101665W WO 0153457 A3 WO0153457 A3 WO 0153457A3
Authority
WO
WIPO (PCT)
Prior art keywords
neurodegenerative disorders
vaccines against
against neurodegenerative
disease
pharmaceutical compositions
Prior art date
Application number
PCT/US2001/001665
Other languages
French (fr)
Other versions
WO2001053457A2 (en
Inventor
Pramod K Srivastava
Original Assignee
Univ Connecticut Health Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Connecticut Health Ct filed Critical Univ Connecticut Health Ct
Priority to AU2001229592A priority Critical patent/AU2001229592A1/en
Publication of WO2001053457A2 publication Critical patent/WO2001053457A2/en
Publication of WO2001053457A3 publication Critical patent/WO2001053457A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to pharmaceutical compositions comprising antigenic molecules for use as vaccines for the treatment and prevention of neurodegenerative disorders and diseases, such as Alzheimer's Disease. The invention further relates to methods for the use of such pharmaceutical compositions as immunotherapeutic agents for treating and protecting against such neurodegenerative disorders and disease.
PCT/US2001/001665 2000-01-21 2001-01-18 Vaccines against neurodegenerative disorders WO2001053457A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001229592A AU2001229592A1 (en) 2000-01-21 2001-01-18 Vaccines against neurodegenerative disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48921900A 2000-01-21 2000-01-21
US09/489,219 2000-01-21

Publications (2)

Publication Number Publication Date
WO2001053457A2 WO2001053457A2 (en) 2001-07-26
WO2001053457A3 true WO2001053457A3 (en) 2002-04-18

Family

ID=23942899

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/001665 WO2001053457A2 (en) 2000-01-21 2001-01-18 Vaccines against neurodegenerative disorders

Country Status (2)

Country Link
AU (1) AU2001229592A1 (en)
WO (1) WO2001053457A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8460676B2 (en) 2004-11-05 2013-06-11 Novartis Ag Composition comprising VLP and amyloid beta peptide
US8673593B2 (en) 2003-11-08 2014-03-18 Elan Pharmaceuticals, Llc Antibodies to alpha-synuclein

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5926700A (en) 1999-07-08 2001-01-30 Stressgen Biotechnologies Corporation Induction of a th1-like response in vitro
IL153474A0 (en) 2000-06-26 2003-07-06 Stressgen Biotechnologies Corp Human papilloma virus treatment
MXPA03006971A (en) 2001-02-05 2004-05-05 Stressgen Biotechnologies Corp Hepatitis b virus treatment.
AU2003205623A1 (en) * 2002-01-18 2003-07-30 Cytos Biotechnology Ag Prion protein carrier-conjugates
IL163812A0 (en) 2002-03-05 2005-12-18 Univ Ramot Immunizing composition and method for inducing an immune response against the -secretase cleavage site of amyloid precursor protein
WO2004007743A2 (en) * 2002-07-17 2004-01-22 Coley Pharmaceutical Gmbh Use of cpg nucleic acids in prion-disease
WO2004016282A1 (en) 2002-07-19 2004-02-26 Cytos Biotechnology Ag Vaccine compositions containing amyloid beta1-6 antigen arrays
US8697082B2 (en) 2002-11-01 2014-04-15 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US9034337B2 (en) 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
DE10303974A1 (en) * 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
US8147833B2 (en) 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
DK3067066T3 (en) 2007-02-23 2019-05-20 Prothena Biosciences Ltd PREVENTION AND TREATMENT OF SYNUCLEINOPATIC AND AMYLOIDOGENIC DISEASE
EP2185160B1 (en) * 2007-08-31 2019-02-13 Neurimmune Holding AG Method of providing patient specific immune response in amyloidoses and protein aggregation disorders
US10383887B2 (en) 2008-02-20 2019-08-20 New York University Preventing and treating amyloid-beta deposition by stimulation of innate immunity
US9605054B2 (en) * 2009-02-23 2017-03-28 The Board Of Trustees Of The University Of Illinois Composition and method for treating a tauopathy
WO2015179867A1 (en) * 2014-05-23 2015-11-26 University Of South Florida Methods, antibodies, and vaccines utilizing epitopes of alpha synuclein for treatment of parkinson's disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739109A (en) * 1988-12-16 1998-04-14 Advanced Immunit Inc. Method of treating neuroinflammatory degenerative diseases
US5780587A (en) * 1990-08-24 1998-07-14 President And Fellows Of Harvard College Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
US5811243A (en) * 1993-08-31 1998-09-22 Duke University Methods and compositions for binding tau and MAP2c proteins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739109A (en) * 1988-12-16 1998-04-14 Advanced Immunit Inc. Method of treating neuroinflammatory degenerative diseases
US5780587A (en) * 1990-08-24 1998-07-14 President And Fellows Of Harvard College Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
US5811243A (en) * 1993-08-31 1998-09-22 Duke University Methods and compositions for binding tau and MAP2c proteins

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AL-SABBAGH A.M. ET AL.: "Decreased CNS Inflammation and Absence of Clinical Exacerbation of Disease After Six Months Oral Administration of Bovine Myelin in Diseased SJL/J Mice With Chronic Relapsing Experimental Autoimmune Encephalomyelitis", JOURNAL OF NEUROSCIENCE RESEARCH, vol. 45, 1996, pages 424 - 429, XP002943101 *
CEDERBAUM J.M.: "A Phase I Study of Recombinant Human Ciliary Neurotrophic Factor (rHCNTF) in Patients with Amyotrophic Lateral Sclerosis", CLINICAL NEUROPHARMACOLOGY, vol. 18, no. 6, 1995, pages 515 - 532, XP002943105 *
LADU M.J. ET AL.: "Purification of Apolipoprotein E Attenuates Isoform-specific Binding to beta-Amyloid", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 16, April 1995 (1995-04-01), pages 9039 - 9042, XP002943103 *
MC GEER P.L. ET AL.: "Apolipoprotein E4 (ApoE4) but not ApoE3 or ApoE2 potentiates beta-amyloid protein activation of complement in vitro", BRAIN RESEARCH, vol. 749, 1997, pages 135 - 138, XP002943102 *
SANAN D.A. ET AL.: "Apolipoprotein E Associates with beta Amyloid Peptide of Alzheimer's Disease to Form Novel Monofibrils", J. CLIN. INVEST., vol. 94, August 1994 (1994-08-01), pages 860 - 869, XP002943104 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8673593B2 (en) 2003-11-08 2014-03-18 Elan Pharmaceuticals, Llc Antibodies to alpha-synuclein
US8460676B2 (en) 2004-11-05 2013-06-11 Novartis Ag Composition comprising VLP and amyloid beta peptide
US8617566B2 (en) 2004-11-05 2013-12-31 Novartis Ag Composition comprising VLP and amyloid beta peptide

Also Published As

Publication number Publication date
AU2001229592A1 (en) 2001-07-31
WO2001053457A2 (en) 2001-07-26

Similar Documents

Publication Publication Date Title
WO2001053457A3 (en) Vaccines against neurodegenerative disorders
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
HK1087398A1 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
BG66083B1 (en) Pharmaceutical compositions containing antibodies, and antibodies for prevention andf treatment of amyloidogenic disease
TW264480B (en)
IL245956B (en) Novel immunogenic compositions for the prevention and treatment of meningococcal disease
GB0129260D0 (en) Pharmaceutical compositions and their uses
WO2005004802A3 (en) N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease
WO2005004803A3 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
IL149924A0 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
IL188506A0 (en) Use of an immunogen for preparation of pharmaceutical composition for treating alzheimer's disease
WO2006001877A3 (en) Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
WO2004062625A3 (en) Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease
AU2002314914A1 (en) Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases
WO2005018545A3 (en) Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease
HK1104280A1 (en) Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases
WO2003068147A3 (en) Treatments for neurotoxicity in alzheimer’s disease
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
WO2005046605A3 (en) Compositions and methods of treating neurological diseases
WO2007063428A3 (en) Pharmaceutical compositions comprising carboxyalkylsulfonic acids
WO2003066806A3 (en) Therapeutic use of aziridino compounds
WO2004091522A3 (en) Method for treating neurodegenerative disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP